Core Insights - The Mexican spinal implant and vertebral compression fracture (VCF) market was valued at over $135 million in 2023 and is projected to grow at a CAGR of 6.1%, exceeding $205 million by 2030 [1][3]. Market Overview - The report covers various segments including cervical fixation devices, thoracolumbar fixation devices, interbody devices, motion preservation devices, VCF treatment, electrical stimulation devices, and spinal surgery instrumentation [2][6]. - The market analysis includes unit sales, average selling prices, market value, and growth trends, with projections extending to 2030 and historical data from 2020 [3][7]. Market Trends - There is a growing interest in minimally invasive surgery (MIS) in Mexico, which is gaining popularity due to shorter recovery times and fewer complications, although its adoption is still behind more advanced markets [3]. - The healthcare system in Mexico is primarily hospital-focused, resulting in a lower rate of outpatient procedures compared to other Latin American countries, which poses challenges for the adoption of advanced surgical technologies [4]. Competitive Landscape - ZimVie/Highridge Medical is the market leader in 2023, holding significant shares in cervical fixation, thoracolumbar fixation, and interbody device segments, supported by a strong distribution network [5]. - Medtronic ranks as the second-largest player, leading in the VCF segment with its PVA device, while DePuy Synthes is third, primarily generating revenue from fixation devices [5]. Market Segmentation - Cervical fixation devices include anterior and posterior types, while thoracolumbar fixation devices are categorized based on degenerative treatments and approaches [6]. - Interbody devices encompass various types such as ALIF, PLIF, and expandable devices, while motion preservation devices include artificial discs and dynamic stabilization [6]. Research Scope - The report covers the Mexican market with a base year of 2023 and a forecast period from 2024 to 2030, including quantitative and qualitative analyses of market size, procedure volume, and competitive dynamics [7][8].

Financial Data and Key Metrics Changes - Total revenue for Q2 2024 was $117 million, reflecting a decrease of 1.5% in reported rates and a modest decline of 0.4% in constant currency [11][12] - Adjusted EBITDA for Q2 2024 was $16.1 million, representing a margin of 13.8% [14] - Adjusted earnings per share for Q2 2024 was $0.13 on a fully diluted share count of 27.4 million shares [14] Business Line Data and Key Metrics Changes - The dental implant portfolio saw strong traction with new products, contributing to market share gains [4][5] - Biomaterials offerings experienced modest growth, outpacing market growth, indicating potential future growth for implant offerings [7] - The digital portfolio grew high single digits, driven by over 20% growth in the Implant Concierge service [8][10] Market Data and Key Metrics Changes - U.S. third-party net sales for Q2 2024 were $69.3 million, a slight increase of 0.1% [11] - Outside the U.S., third-party net sales were $47.5 million, a decrease of 3.8% on a reported basis [12] - The Asia Pacific market showed a reported decline of 6.9%, but grew 1.1% in constant currency, indicating stability in certain regions like Japan and India [39] Company Strategy and Development Direction - The company aims to enhance its premium dental implant market position while expanding its digital capabilities [20] - Focus on innovation in product offerings, including the introduction of GenTek Restorative Components and partnerships with Medit for imaging solutions [6][9] - The strategy includes improving operational efficiency and achieving a 15% plus adjusted EBITDA margin by April 2025 [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the execution and resilience of the portfolio despite market challenges [10][18] - The outlook for Q3 2024 anticipates a sequential decline in revenue due to seasonal impacts, with expected adjusted EBITDA margins around 12% [16][26] - Management remains cautious about market recovery, indicating that underlying challenges persist [26] Other Important Information - The company finalized the sale of its Spine business on April 1, 2024, which is reflected in discontinued operations [11] - Cash as of the end of Q2 2024 was $78.6 million, with gross debt approximately $235 million [15] Q&A Session Summary Question: Company positioning within dental market - Management highlighted the unique assets and premium positioning in the dental implant market, focusing on organic growth and potential complementary product categories [19][20] Question: Impact of iTero Lumina's restorative launch delay - Management acknowledged the delay's impact on 2024 projections, attributing missed digital sales primarily to scanner sales [22][23] Question: Q3 revenue guidance and market demand - Management indicated that Q3 is expected to be lower due to seasonal trends, with cautious optimism about patient demand stabilizing [25][26] Question: Insights from planning software and market trends - Management noted growth in guided surgery and biomaterials as leading indicators of market stabilization [32][33] Question: Strategic considerations regarding potential partnerships - Management emphasized the importance of maintaining differentiation and open strategies in the market, while being prepared for future opportunities [35][36] Question: Capacity and performance in Asia - Management reported minimal exposure to China, with positive growth in other Asia Pacific markets like India and Australia [38][39]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41242 | --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------------- ...

ZimVie Reports Second Quarter 2024 Financial Results • Third Party Net Sales from Continuing Operations of $116.8 million • Net Loss from Continuing Operations of $(9.6) million; Net Loss margin of (8.2%) • Adjusted EBITDA[1] from Continuing Operations of $16.1 million; Adjusted EBITDA[1] margin of 13.8% • Reduced debt to $235.1 million, ended quarter with cash balance from Continuing Operations of $78.6 million PALM BEACH GARDENS, Florida, August 1, 2024 (GLOBE NEWSWIRE) – ZimVie Inc. (Nasdaq: ZIMV), a glo ...

Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com Allison Johnson • Allison.Johnson@ZimVie.com (561) 319-6130 ZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoratio ...

PALM BEACH GARDENS, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced that the company will be participating in two upcoming investor conferences. Investor Contact Information: Gilmartin Group LLC Marissa Bych • Marissa@gilmartinir.com ZimVie will be presenting at the upcoming Stifel 2024 Jaws & Paws Conference. ZimVie's management is scheduled to present on Thursday, May 30, 2024, at 11:30 a.m. Eastern Time. ZimVie's manag ...

PALM BEACH GARDENS, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced that the company will be participating in two upcoming investor conferences. ZimVie will be presenting at the upcoming Stifel 2024 Jaws & Paws Conference. ZimVie's management is scheduled to present on Thursday, May 30, 2024, at 11:30 a.m. Eastern Time. ZimVie's management will also be presenting at the 45th Annual Goldman Sachs Global Healthcare Conferen ...

ZimVie Inc. (NASDAQ:ZIMV) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Marissa Bych - IR, Gilmartin Group LLC Vafa Jamali - President and CEO Richard Heppenstall - CFO Conference Call Participants Matt Miksic - Barclays Operator Good afternoon and welcome to ZimVie's First Quarter 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41242 ZIMVIE INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 87-2007795 | | --- | --- | | ( State or oth ...

Exhibit 99.1 ZimVie Reports First Quarter 2024 Financial Results PALM BEACH GARDENS, Florida, May 8, 2024 (GLOBE NEWSWIRE) – ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2024. Management will host a corresponding conference call today, May 8, 2024, at 4:30 p.m. Eastern Time. Adjusted EBITDA[1] for the first quarter of 2024 was $12.5 million, or 10.5% of third party net sales, an increase of $1.8 million or 17 ...